Myocardial ischemia is characterized by the liberation of adenosine and by complement-mediated inflammation. We have reported that amidated C3, formed when ammonia (NH3) disrupts the thiolester bond of C3, serves as an alternative pathway convertase, generates C5b-9, and stimulates phagocytic oxidative metabolism. We investigated whether the deamination of adenosine by adenosine deaminase in hematopoietic cells might liberate sufficient ammonia to form amidated C3 and thereby trigger complement-mediated inflammation at ischemic sites.
Introduction
There is substantial evidence for the participation of complement proteins in ischemic myocardial injury. Nearly 20 years ago Hill and Ward demonstrated that a chemotactically active form of C3 was generated by the incubation of human or rat serum with a tissue homogenate from infarcted rat hearts.
Chemotactic activity was inhibited in vitro by incubation with an antibody to C3 and in vivo by depletion of rat C3 with cobra venom factor. The authors proposed that an enzyme in infarcted myocardium acted directly on C3 to generate inflammatory sequelae (1) . Subsequent studies have provided ample confirmation of complement-dependent effects in experimental models of myocardial infarction in the rat, the dog, and the baboon, and have expanded the role of C3 to the mediation of physiologic, electrocardiographic, and histologic consequences of myocardial infarction (2) (3) (4) (5) .
However, the mechanism by which C3 mediates these sequelae has not been established. In addition to the direct activation mechanism suggested by Hill and Ward, subsequent studies have proposed the participation of the alternative complement pathway in an antibody-independent mechanism, while more recent investigations have focused on the role of subcellular components such as cardiolipin in antibody-independent activation of complement in normal hearts (6) (7) (8) (9) .
Because increases in local concentrations ofadenosine also accompany myocardial ischemia (10), we propose that the increased concentrations of adenosine liberated at infarcted sites provide substrate for erythrocyte (RBC)' adenosine deaminase (ADA). In this paper we demonstrate how enzymatic deamination of adenosine releases NH3, which in turn leads to the formation of amidated C3, a biochemically reactive form of the third component of complement which has been shown to trigger complement-mediated inflammation.
Formed when free-base NH3 disrupts the internal thiolester bond ofC3, amidated C3 engenders inflammatory sequelae by virtue of its "C3b-like" functions, including its ability to serve as an alternative pathway convertase, its amplification of C3 and C5 cleavage, its formation of the membrane attack complex, and its ability to bind to membrane complement receptors on phagocytic cells (1 1-13) . In the kidney amidated C3 is formed by the reaction of plasma C3 with free-base NH3 in the peritubular capillaries (12, 13 (14) .
Adenosine (Calbiochem-Behring Corp., La Jolla, CA) was dissolved in KPi/Hepes for a stock concentration of 16 mM. 2'-Deoxycoformycin (Pentostatin), a tight-binding inhibitor of ADA (14) (15) (16) (17) , was the gift ofMartin L. Black ofthe Warner Lambert Co., Ann Arbor, MI. The compound was dissolved in water at pH 8.4 and stored in a concentration of 0.5 mg/ml according to manufacturer's instructions.
5 X 108 human RBC in KPi/Hepes buffer were incubated in a 37°C water bath for varying time periods in the presence or absence of adenosine and purified human C3 (2 mg/ml). After the appropriate incubation period the reaction mixtures were pelleted and the supernatants were withdrawn and aliquotted for measurement of NH3 concentration and analysis by affinity chromatography. In experiments assessing inhibition by 2'-deoxycoformycin, RBC were preincubated with 0.4 AM deoxycoformycin in KPi/Hepes buffer for 30 min at 37°C before the addition of C3 and/or adenosine.
NH3 assay. The NH3 assay used is a published method for the determination of total NH3 by the Bertholet reaction (18) . Briefly, Dowex 5OW-X4, 100-200 mesh (Sigma Chemical Co., St. Louis, MO) was washed as follows: one part of the resin was mixed with two parts of 2.5 M sodium hydroxide and allowed to stand for 15 min with occasional mixing. After settling of the resin, the supernatant was decanted. The resin was then washed three to five times with distilled water, permitted to settle, and the water decanted. These washes were continued until the pH of the supernatant was neutral. One part resin was then mixed with two parts dilute acetic acid (2 ml glacial acetic acid/100 ml distilled water) and allowed to settle. After the acidic supernatant was decanted the resin was washed several times with distilled water and stored under water at room temperature.
Stock phenol reagent was made by dissolving 25 g of phenol and 130 mg of sodium nitroprusside in 500 ml of NH3-free distilled water. Phenol reagent was stored in a light-impermeable bottle at room temperature. Alkaline hypochlorite reagent was made by dissolving 6.25 g of sodium hydroxide in 200 ml of NH3-free distilled water; after cooling of the mixture, 10 ml of 5.25% sodium hypochlorite was added. Volume was brought to 250 ml with NH3-free distilled water and the mixture was stored in a polyethylene bottle at room temperature.
The NH3 standard was made by dissolving 52.9 mg ofreagent grade ammonium sulfate [(NH4)2SO4J in a final vol of 125 ml of NH3-free distilled water and was stored at 4°C. For assay of NH3 production 0.500 ml of washed resin was placed in 16 X 100-mm glass test tubes. The supernatant from the sample to be tested was pipetted directly onto the resin and gently mixed. 10 ml of NH3-free distilled water was then added to each tube, the resin was allowed to settle, and the water was aspirated after settling. This step was repeated for a total of three washes, and after the third settling the water was aspirated just to the level of the resin. 1 ml of the phenol stock was then added to each test tube, mixed, and allowed to stand for 3 min at room temperature. 1 ml of the alkaline hypochlorite stock was then added to each test tube, mixed, and allowed to stand for 15 min at 37°C in a stationary water bath. 3 ml ofNH3-free distilled water was then added to each test tube, mixed, and the resin allowed to settle. Supernatant was withdrawn from the resin and the OD was measured at 630 nm on a UV/VIS spectrophotometer.
A standard curve consisting ofconcentrations ofthe NH3 standard ranging from 50 to 400 nmol/ml was performed with each day's samples, which were run in duplicate. As an internal control, a commercially available NH3 standard (Sigma Chemical Co.) was used to confirm the accuracy of the standard curve. Concentration of NH3 was calculated for each sample from the following formula: absorbance of sample/absorbance of standard x concentration of standard = concentration of sample.
Isolation ofC3. Human C3 was isolated from fresh plasma according to the methods of Tack et al. (19) . Possible trace contaminants (IgG, IgA, and C5) were absorbed by affinity chromatography on cyanogen bromide-activated Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ) to which goat anti-human IgG, goat anti-human IgA, and goat anti-human C5 had been coupled according to manufacturer's instructions. C3 used in these experiments was therefore free of IgG, IgA, and C5 by SDS-PAGE, by double immunodiffusion against the above-named antibodies, and by affinity depletion of otherwise undetectable minor contaminants.
Affinity chromatography. Goat antiserum to human C3 (the kind gift of Dr. Brian F. Tack, Scripps Clinic, San Diego, CA), was treated with caprylic acid according to the procedure ofSteinbuch and Audran (20). After removal of caprylic acid by dialysis at 4°C in PBS (pH 7.4), purity of the IgG fraction was checked on SDS-PAGE. The IgG fraction was then coupled to cyanogen bromide-activated Sepharose 4B according to manufacturer's instructions.
For affinity columns 0.5 ml of affinity reagent was equilibrated with 50 mM KH2PO4, pH 7.5, 2 mM MgSO4, and 75 mM NaCl (KPi/NaCl) in 1 X 15-cm disposable glass columns (Pierce Chemical Co., Rockford, IL). 244 Ml of supernatant from reaction mixtures was applied to the affinity matrix, which was then washed with 10 ml of KPi/NaCl. Neither protein nor tritium was ever detected in these eluates. C3 was eluted with 0.02 M HCI and 800-Ml fractions were collected. After neutralization with 100 mM Tris, pH 8.0, and 10 mM EDTA protein content was quantitated by measurement ofabsorbance at 280 nm. Fractions containing protein were pooled and dialyzed repetitively in PBS to remove unbound radiolabel, and an aliquot was removed for measurement of thiolester disruption as described below. The remainder of each pool was then treated with reducing buffer, boiled, and stored at -70°C before SDS-PAGE on 7.5% polyacrylamide gels according to the method of Laemmli (21) .
Titration ofthiolester disruption. Quantitation of thiolester disruption was performed by radioalkylation ofthe exposed sulfhydryl group, according to published procedures (1 1, 22, 23). Briefly, reaction supernatants containing human C3 were incubated with 1.5 Ml of [3H]-iodoacetic acid (sp act, 10 mCi/mM; Amersham Corp., Arlington Heights, IL) for 90 min in a 37°C water bath. Samples were then subjected to affinity chromatography for retrieval of human C3. After elution from the affinity matrix all samples containing C3 were pooled and dialyzed overnight against PBS to remove unbound [3H]iodoacetic acid. Concentration of C3 was determined by measurement of absorbance at 280 nm; incorporation of [3H]iodoacetic acid was determined by counting 100 Ml of each sample in a scintillation counter (Beckman Instruments, Inc., Palo Alto, CA). Results are expressed as moles of
[3H]iodoacetic acid/mole C3. Preparations of native C3 used in these experiments incorporated 0.06 mol [3H]iodoacetic acid/mol C3; thus, minimal hydrolysis during purification resulted in disruption of the thiolester in 6% of C3 molecules.
Neutrophil studies. Neutrophils were isolated from the heparinized peripheral blood of healthy adult donors by dextran sedimentation, Ficoll (Pharmacia Fine Chemicals) separation in lymphocyte separation medium (Litton Bionetics, Inc., Kensington, MD), and hypotonic lysis of RBC. Purity and viability (the latter assessed by trypan blue exclusion) were 2 97% with these methods.
For experiments quantitating release of neutrophil products, amidated C3 was made by incubating purified human C3 (3.65 mg/ml) with 1 M NH4Cl (final concentration, 0.1 M NH4C1) in 0.1 M Tris, 0.01 M EDTA, pH 8.0, for 80 min in a 37°C water bath, according to our published methods (1 1-13). Amidated C3 was then dialyzed exhaustively in PBS to remove excess NH4Cl, and thiolester disruption was quantitated by the method described above. All preparations of amidated C3 exhibited a disrupted thiolester in > 85% of the molecules. As described above, these preparations were absorbed with anti-C5, anti-IgG, and anti-IgA Sepharose 4B before amidation to remove possible trace contaminants. For coupling to microspheres, amidated C3 (0.4 mg/ml) and gelatin (0.5 mg/ml) were dialyzed overnight in 0.1 M NaH2CO3, 0.5 M NaCl, pH 8.5, and then incubated with 1 X 1010 1-Mm MX-Covaspheres (Duke Scientific Corp., Palo Alto, CA) for 60 min at room temperature. Microspheres with deposited ligands were then washed three times with PBS/l% gelatin and resuspended to 1 ml in the same buffer, according to our published methods (11, 24) . This procedure resulted in the deposition of -14,000 molecules of ami-dated C3/microsphere. Microspheres coated with iC3b and C3b were tested simultaneously. These results have been previously published (24) .
The production of superoxide from 5 X 105 neutrophils was assessed by measuring the SDD-inhibitable reduction ofcytochrome c at 550 nm according to the microassay of Pick and Mizel (25) . For superoxide assays, microspheres coated with amidated C3 or gelatin were used as the stimulus in a ratio of 1,000:1 (spheres/PMNs). For degranulation assays, PMNs were pretreated with cytochalasin B (5 1sg/ml) and then stimulated with microspheres coated with amidated C3 in a ratio of 100:1 (spheres/PMNs). Myeloperoxidase was measured by the method of Webster and Henson (26), and lactoferrin was measured by the method of Hetherington et al. (27) . The results of these assays are expressed as percent of total cellular myeloperoxidase or lactoferrin, determined after neutrophil lysis in 0.1% Triton X-100 in PBS, 0.5 M NaCl.
Statistics. Data were analyzed according to t test; P < 0.05 was considered significant. the thousandfold preponderance of RBC in human blood makes them the major cellular source of NH3 in the bloodstream. As shown in the bottom graph, the time course of NH3 production reached a maximum between 1 and 2 h when 5 X 108 RBC were incubated at 37°C. Thus, for all subsequent experiments detailed in this paper, 4 mM adenosine was incubated for 2 h at 37°C and physiologic pH with 5 X 108 human RBC, -1/10 the number of RBC in a milliliter of human blood. Table I shows that production of NH3 by RBC occurred only in the presence of adenosine and was independent of the presence of C3. NH3 production was not detected in the supernatants from control mixtures of 5 X 108 human RBC and C3, or in the presence 4 mM adenosine without RBC. When the glucose concentration in the buffer system was varied between 5 and 50 mM, when the pH of the buffer was varied between 7.0 and 8.0, or when the mixtures were bubbled with nitrogen to replace oxygen, NH3 production was not affected (data not shown). These observations are consistent with previous demonstrations that the activity of the enzyme ADA is stable to pH and ionic strength (28). Fig. 2 shows that NH3 production by 5 X I0O human RBC was inhibited by increasing concentrations of 2'-deoxycoformycin. Maximal inhibition occurred at a concentration of 0.4 ,uM deoxycoformycin, which accords with previous publications (14, 16) . These results confirm that NH3 measured in Fig.  1 and Table I is produced by the ADA-mediated deamination of adenosine.
The production of NH3 after deamination of adenosine by normal human RBC was sufficient for the formation of amidated C3 (Fig. 3) . When purified human C3 (2.05 mg/ml) was incubated with 5 X 1o8 human RBC in the presence of 4 mM adenosine, disruption of the C3 thiolester site, as measured by radioalkylation of the exposed sulfhydryl group, increased more than twofold over that measured in C3 alone, in C3 with RBC, or in C3 with adenosine (P < 0.05). Thus, only the reaction that produced NH3 resulted in statistically significant disruption of the C3 thiolester.
As shown in Fig. 4 , the generation of amidated C3 was abolished when NH3 production was inhibited by the preincubation of RBC with 0.4 ,uM deoxycoformycin (P < 0.001). Thus, NH3 produced by the incubation of RBC with adenosine was sufficient to disrupt the thiolester bond in -15% of C3 molecules, whereas the preincubation of RBC with deoxycoformycin and the subsequent inhibition of ADA reduced disruption of the C3 thiolester by 60%. Only 6% of C3 molecules exhibited a titrable sulfhydryl group after deoxycofor- (Fig. 3) is not attributable to proteolytic degradation of C3.
The reaction of amidated C3 with PMN led to the release of superoxide, myeloperoxidase, and lactoferrin, as shown in Fig. 6 . Although amidated C3 is not so potent in this regard as phorbol myristate acetate, its effects equal or surpass those reported for other C3 ligands when bound to prototypic surfaces (24) .
Discussion
The participation of the complement proteins in postischemic myocardial necrosis has been well established over nearly two decades of investigation. After Hill and Ward's original demonstration that chemotactic activity and neutrophilic infiltration could be ablated by pharmacologic depletion of C3 with cobra venom factor in a rat model of myocardial infarction, other investigators used similar means to limit the degree of tissue damage after coronary artery occlusion, as assessed both by histology of epicardial biopsies and by the ratio of creatine kinase to ST segment elevation in canine models (1-3) .
The clinical importance of these observations was emphasized by the demonstration of significant decreases in serum levels of several complement proteins (C1, C4, C2, and C3) in patients during the first 72 h after myocardial infarction (6) and was confirmed in a model of infarction in nonhuman primates, where deposition ofC3 was localized to sarcolemmal membranes of infarcted baboon heart but was absent in animals depleted of C3 with cobra venom factor before occlusion (5) . Although experimental formulations of subcellular membrane constituents, such as cardiolipin vesicles, are now known to activate complement independently of antibody in studies with normal cardiac tissue (7) (8) (9) , the factors responsible for complement-mediated inflammation after ischemia have remained unidentified. In this study we propose that the deamination of adenosine, found in increased concentrations at ischemic tissue sites, liberates sufficient NH3 to generate the potently active mediator, amidated C3.
The formation of amidated C3 by physiologic nucleophiles is a predictable consequence of the biochemistry of C3 and its internal thiolester bond and has been thoroughly elucidated (22, 23, 29, 30) . Within the a-chain of C3 there is a conserved sequence of seven amino acids (Gly-Cys-Gly-Glu-Glu-AsnMet) within which is contained the reactive thiolester bond which joins the cysteinyl residue to the second glutamyl residue. Nucleophilic amines such as NH3 or methylamine attack the thiolester directly, breaking the bond and forming an amide linkage at the glutamyl carbonyl. This reaction is stoichiometric and specific only for the second glutamyl carbonyl; amidated thiolester peptides have been sequenced for confirmation (23, 29) .
Modification of C3 by nucleophiles such as methylamine or free-base NH3 endows the modified protein with C3b-like properties (I 1-13, 31-33). Because of its structural similarities with C3b, NH3-modified C3 (amidated C3) likewise forms the convertase for the alternative pathway and potentiates the amplification loop. By serving as an alternative pathway convertase amidated C3 cleaves C5 and promotes both the assembly of the membrane attack complex (C5b-9) and the libera-On our dose-response curve (Fig. 1, top) (12, 13) . Thus, concentrations of adenosine that correspond quite closely with those likely to be released at isch-$ ; -66 emic sites will provide sufficient NH3 for the generation of amidated C3 after deamination of adenosine by RBC ADA.
Other investigators have measured NH3 produced by the 45 deamination of adenosine in human RBC (36) . In one such study the rate of NH3 production was 0.2 mmol/min per ml 29 packed RBC with 1 mM adenosine as substrate. This activity corresponds quite closely to our measurement of 0.187 mmol NH3/min per ml packed RBC in the presence of 1 mM adenosine (Fig. 1) . Neither human plasma nor platelets are effective sources of ADA, unlike other species (28). Thus, our observa-1 2 3 4 5 6 7 8 tions on the avidity with which human RBC incorporate Figure 5 . 7.5% SDS-PAGE gel displaying eluates released after affinadenosine and on the rate of NH3 production after such incority chromatography on anti-C3 Sepharose 4B. Under standard assay conditions we were readily able to show that specific inhibition of RBC ADA by 2'-deoxycoformycin tion of the chemotaxin CSa (12, 13) . Finally, amidated C3 binds to membrane complement receptors on PMN and monocytes and triggers a chemiluminescent response (1 1). A review of the biochemical and biologic properties of amidated C3 has recently been published (34) .
As we have shown in these studies, the binding ofamidated C3 to neutrophil membranes is a potent stimulus for the release of superoxide, myeloperoxidase, and lactoferrin as well. Indeed, with amidated C3 as the ligand on a prototypic surface, the amounts of inflammatory mediators released from the neutrophil equal, and in some cases surpass, the effects of other complement ligands such as C3b or iC3b (24) . By triggering both the alternative pathway and the release of destructive products from activated neutrophil, amidated C3 thus sets in motion a cascade of potent inflammatory consequences.
In two experimental models of chronic renal disease we have provided both immunochemical and direct quantitative evidence of the link between increased renal ammoniagenesis and complement activation by amidated C3 (12, 13) . Because of the well-established increase in liberation of adenosine by ischemic tissue, ammoniagenesis may also be promoted at ischemic sites as well (10, 35) . For example, although the concentration of adenosine in normoxic plasma is 0.100 ,uM, Rubio and colleagues measured a minimum concentration of 0.750 ,M in extracellular water after 30-60-s occlusions of the left coronary artery in dogs (10) . However, both the avid uptake of adenosine by RBC and its subsequent deamination within the cell can be expected to lower extracellular adenosine levels. Since > 95% of available adenosine is readily taken up by the cellular elements of blood (28), whole blood levels of adenosine plus its products, NH3 and hypoxanthine, probably exceed by several-fold the reported levels of adenosine in extracellular water. inhibited both the production of NH3 and the formation of amidated C3 (Figs. 2 and 4) . Although presently under study as a chemotherapeutic agent in hematogenous malignancies (14, 37, 38) , 2'-deoxycoformycin may have additional applications. Our results suggest that 2'-deoxycoformycin may modulate comnplement-mediated necrosis at sites of adenosine release; study of the effects of deoxycoformycin in animal models of myocardial infarction is surely warranted. These experiments provide a biochemical mechanism for the mediation of complement-dependent injury at sites of increased adenosine concentration. Liberation of NH3 by RBC ADA, even at 10% of the normal hematocrit, is sufficient for nucleophilic disruption of the C3 thiolester bond. As previously shown, the formation of amidated C3 leads to enzymatic activation of the alternative complement pathway, to the production of C5a and C5b-9, and to the initiation of phagocytic oxidative metabolism and neutrophil degranulation. Such a milieu could readily support neutrophil activation and the generation of oxygen-free radicals, which have been recently implicated in postischemic myocardial necrosis and reperfusion injury (39, 40) . Inhibition of ADA by 2'-deoxycoformycin may constitute a novel strategy for controlling C3-dependent sequelae at ischemic sites.
